Despite this success, investors were unimpressed with the topline data, with Syndax’s stock dropping by 25.6%, from $21.78 ...

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

On Tuesday, Syndax Pharmaceuticals Inc (NASDAQ:SNDX) revealed topline results from the relapsed or refractory (R/R) mutant ...

Mizuho Securities analyst Salim Syed has maintained their bullish stance on SNDX stock, giving a Buy rating yesterday. Salim Syed has given ...

Syndax Pharmaceuticals (SNDX) stock dropped ~23% after the company posted Phase 2 trial data for its AML candidate, revumenib ...

While awaiting an FDA decision for its small molecule revumenib in one form of acute leukemia, Syndax Pharmaceuticals is ...

Scotiabank analyst George Farmer lowered the firm’s price target on Syndax (SNDX) to $18 from $23 and keeps a Sector Perform rating on ...

Syndax Pharmaceuticals (Nasdaq: SNDX) has announced that its Phase II AUGMENT-101 trial of experimental drug revumenib ...

Syndax Pharmaceuticals (NASDAQ:SNDX – Free Report) had its price target boosted by HC Wainwright from $45.00 to $47.00 in a research note issued to investors on Wednesday morning,Benzinga reports. The ...

Detailed price information for Immunitybio Inc (IBRX-Q) from The Globe and Mail including charting and trades.

WALTHAM, Mass. - Syndax Pharmaceuticals (NASDAQ:SNDX), a developer of cancer therapies, today announced the immediate appointment of Steven Closter as Chief ...